Clinical Trial Update: Genetic and Molecular Mechanisms in Assessing Response in Patients With Prostate Cancer Receiving Enzalutamide Therapy [Phase 2]

View source ↗

Summary

This Phase 2 clinical trial update investigates genetic and molecular factors associated with response to enzalutamide in prostate cancer, including castration-…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bone Metastasis
• Castration-resistant Prostate Cancer
• Prostate Adenocarcinoma
• Prostate Cancer
• Soft Tissue Metastasis

Drugs mentioned

• Xtandi (enzalutamide)

Snippet

Sponsor: OHSU Knight Cancer Institute | Conditions: Castration-Resistant Prostate Carcinoma, Metastatic Malignant Neoplasm in the Bone | Phase 2 | Status: COMPLETED | Results posted: 2021-01-13